Vildagliptin（274901-16-5）

Vildagliptin is another oral dipeptidyl peptidase IV (DPP-IV) inhibitor after sitagliptin. It was approved by Novartis Pharmaceutical Co., Ltd. of Switzerland to be listed in the European Union in 2008 for the treatment of type 2 diabetes. Diabetes is a chronic metabolic disease, and its prevalence is increasing year by year. type 2 diabetes is a complex disease with polygenic genetic factors and environmental factors. Dipeptidyl peptidase IV (DPP-IV) inhibitors are a new class of anti diabetes drugs, which promote insulin biosynthesis, secretion and inhibition by induction β Apoptosis, inhibition of glucagon secretion, reduction of food intake and other mechanisms play a hypoglycemic role, and can reverse the worsening condition of pancreatic islet function in diabetes patients while controlling blood sugar, showing a good application prospect. Vegliptin is a representative drug of dipeptidyl peptidase inhibitor. In clinical research, whether used alone or in combination with metformin and insulin, it has shown good anti diabetes effect and tolerance.

Viggliptin is a selective, competitive and reversible DPP24 inhibitor. Glucose-dependent insulin-promoting polypeptide (GIP) and glucagon-like polypeptide 21 (GLP21) are important hormones that maintain glucose concentration in the body, and both have the effect of incretin. In patients with type 2 diabetes, GIP's insulin stimulating effect is impaired. Only GLP21 can play the role of insulin stimulating hormone secretion by acting on the islets β The receptor on the cell membrane promotes the secretion of insulin. GLP21 can also inhibit the secretion of glucagon and gastric emptying, thus increasing satiety (inhibiting appetite). DPP24 combines with protein in many tissues, such as the brush edge of kidney, liver, small intestine membrane, pancreatic duct, lymphocytes, and endothelial cells. It can rapidly inactivate GLP21 by hydrolyzing the second alanine at the N-terminal. This product inhibits the activity of the enzyme by combining with DPP24 to form DPP24 complex, which increases the concentration of GLP21 and promotes the islet β When cells produce insulin, they reduce the concentration of glucagon, thereby lowering blood sugar. There was no significant effect on body weight.

PREVIOUS：Tadalafil（171596-29-5） NEXT：Dapoxetine（119356-77-3）